



INR



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Innovin	16	100.0	0.0	0.0	1.54	4.8	e
2	Neoplastin R	15	100.0	0.0	0.0	1.70	3.9	e
3	Neoplastin Plus	8	100.0	0.0	0.0	2.04	5.8	e*
4	Recombiplastin 2G	14	100.0	0.0	0.0	1.68	4.3	e
5	Other methods	14	100.0	0.0	0.0	1.67	5.4	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)


Fibrinogen OA



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens Thrombin	8	100.0	0.0	0.0	1.01	6.1	e*
2	Stago/STA	20	100.0	0.0	0.0	1.11	6.7	e
3	Fibrinogen Q.F.A.	9	100.0	0.0	0.0	1.11	5.6	e*
4	Other methods	6	100.0	0.0	0.0	1.10	3.2	e


4 additional results were submitted but not published because the method groups were too small. (< results per group)

Activated Prothrombin Time



No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Actin FS	6	100.0	0.0	0.0	41.1	5.9	e
2	Pathromtin SL	7	100.0	0.0	0.0	69.4	2.0	e
3	Stago/STA	22	100.0	0.0	0.0	55.0	8.8	e
4	aPTT-SP	10	100.0	0.0	0.0	42.7	3.9	e
5	Other methods	11	100.0	0.0	0.0	41.1	7.0	e

INR CoaguChek




QUALAB tolerance : 15 %
(< 1.3: +/- 0.2)

INR CoaguChek ()


No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CoaguChek Pro II	870	99.7	0.0	0.3	1.2	3.8	e

Prothrombin time NT



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Innovin	12	100.0	0.0	0.0	100	0.6	e
2	Neoplastin R	13	100.0	0.0	0.0	96	4.8	e
3	Neoplastin Plus	4	100.0	0.0	0.0	93	3.9	e*
4	STA-NeoPTimal	7	100.0	0.0	0.0	91	5.4	e*
5	Recombiplastin 2G	10	100.0	0.0	0.0	100	0.6	e
6	Other methods	15	100.0	0.0	0.0	99	1.6	e


Fibrinogen N




No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens Thrombin	10	100.0	0.0	0.0	2.52	5.1	e
2	Stago/STA	18	100.0	0.0	0.0	2.80	4.2	e
3	Fibrinogen Q.F.A.	14	100.0	0.0	0.0	2.57	6.6	e
4	Fib Clauss (IL)	5	100.0	0.0	0.0	2.71	6.5	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Faktor V




No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	100.0	0.0	0.0	97.8	9.4	e*

aPTT N


No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Actin FS	9	100.0	0.0	0.0	23.2	1.8	e
2	Pathromtin SL	6	100.0	0.0	0.0	39.1	7.6	e*
3	Stago/STA	21	100.0	0.0	0.0	31.7	6.2	e
4	aPTT-SP	13	100.0	0.0	0.0	25.8	7.0	e
5	Other methods	5	100.0	0.0	0.0	35.7	2.5	e

Faktor VII



No.Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 all Participants	5	100.0	0.0	0.0	106.9	8.4	e*


Prothrombin time HT



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Innovin	13	100.0	0.0	0.0	96	3.9	e
2	Neoplastin R	13	100.0	0.0	0.0	92	4.4	e
3	Recombiplastin 2G	11	100.0	0.0	0.0	99	1.4	e
4	Other methods	11	100.0	0.0	0.0	96	3.0	e


4 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti-FXa (unfrakt-Heparin)



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Stago/STA	11	100.0	0.0	0.0	0.36	6.2	e
2	ACL	26	96.2	0.0	3.8	0.55	6.6	e
3	Other methods	11	100.0	0.0	0.0	0.60	7.7	e

Fibrinogen H




QUALAB tolerance : 15 %

No. Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens Thrombin	4	100.0	0.0	0.0	3.21	2.4	e
2	Stago/STA	17	100.0	0.0	0.0	3.34	6.4	e
3	Fibrinogen Q.F.A.	12	100.0	0.0	0.0	3.39	7.6	e*
4	Other methods	9	100.0	0.0	0.0	3.34	5.8	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

aPTT H




QUALAB tolerance : 25 %

aPTT H (Sek)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Actin FS	4	100.0	0.0	0.0	57.5	4.5	e
2	Actin FSL	5	100.0	0.0	0.0	59.5	10.9	e*
3	Stago/STA	15	100.0	0.0	0.0	106.1	12.5	e*
4	aPTT-SP	14	100.0	0.0	0.0	99.8	9.4	e
5	Other methods	4	100.0	0.0	0.0	60.5	9.0	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)


D-dimer



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche (Zitratplasma)	4	100.0	0.0	0.0	0.45	4.6	e
2	Roche (Heparinplasma)	5	100.0	0.0	0.0	0.70	16.9	a
3	STA Liatest	17	94.1	0.0	5.9	0.54	9.4	e
4	Siemens Innovance	13	100.0	0.0	0.0	0.92	5.6	e
5	Pathfast	22	100.0	0.0	0.0	2.32	9.5	e
6	ACL	17	100.0	0.0	0.0	0.97	6.9	e
7	AQT 90 FLEX	6	100.0	0.0	0.0	0.38	4.2	e
8	VIDAS	16	100.0	0.0	0.0	0.69	6.6	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

D-Dimer Triage




QUALAB tolerance : 21 %

D-Dimer Triage (ng/ml)


No.Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Triage	173	92.4	6.4	1.2	409.55	11.1	e

D-dimer qn AFIAS




No.Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 AFIAS	417	77.4	9.4	13.2	0.61	11.6	e

CoaguChek APTT




No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CoaguChek Pro II	7	100.0	0.0	0.0	41.2	6.7	e

INR CCXS




No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CoaguChek XS	1341	99.0	0.4	0.6	2.0	3.3	e

INR HC

No.Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Hemochron j.	6	83.3	16.7	0.0	1.7	7.9	e*


INR MI



QUALAB tolerance : 15 %
(< 1.3: +/- 0.2)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	microINR Expert	19	36.8	57.9	5.3	1.0	17.4	a
2	MicroINR	120	90.8	7.5	1.7	2.0	8.2	e

INR Xprecia




QUALAB tolerance : 15 %
(< 1.3: +/- 0.2)

INR Xprecia ()

No.Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Xprecia	43	97.7	2.3	0.0	1.2	6.7	e

INR Lumira Dx




QUALAB tolerance : 15 %

INR Lumira Dx ()


No.Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Lumira Dx	7	71.4	28.6	0.0	1.3	9.9	e*

Anti-FXa (LMW-Heparin)



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Stago/STA	12	100.0	0.0	0.0	1.58	4.6	e
2	ACL	15	100.0	0.0	0.0	1.52	6.7	e
3	Other methods	19	100.0	0.0	0.0	1.73	8.0	e

Anti-FXa (Rivaroxaban)




MQ tolerance : 20 %

Anti-FXa (Rivaroxaban) (µg/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Stago/STA	15	100.0	0.0	0.0	72.59	8.6	e
2	ACL	12	91.7	0.0	8.3	85.00	13.2	a

Anti-FXa (Apixaban)




MQ tolerance : 20 %

Anti-FXa (Apixaban) (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Stago/STA	6	100.0	0.0	0.0	269.50	5.1	e
2	ACL	5	100.0	0.0	0.0	259.30	7.3	e*


2 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti-FXa (Edoxaban)



No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	43.50	11.1	e*


Hemoglobin



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Hemocue Hb 801	6	83.3	16.7	0.0	114.5	5.4	e*
2	Automat	8	100.0	0.0	0.0	98.8	2.3	e
3	Cyanmethemoglobin	14	85.8	7.1	7.1	99.0	4.2	e*
4	Sysmex X	59	100.0	0.0	0.0	98.8	1.6	e
5	Hemocue	393	93.4	1.8	4.8	98.3	2.7	e
6	Hemocontrol	16	93.7	0.0	6.3	98.5	2.7	e
7	DiaSpect	12	100.0	0.0	0.0	102.0	2.8	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)


Hemoglobin



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex KX21	91	98.9	0.0	1.1	98.9	2.2	e
2	Sysmex PocH - 100i	180	95.6	1.1	3.3	98.2	2.5	e
3	Sysmex XP 300	579	97.9	0.9	1.2	99.1	2.1	e
4	Mythic	221	98.6	0.9	0.5	96.4	3.0	e
5	Sysmex XQ-320	139	97.8	0.0	2.2	100.4	1.6	e
6	Swelab	28	96.4	3.6	0.0	104.6	3.1	e
7	Celltac Alpha (Nihon	52	96.2	0.0	3.8	101.8	2.5	e
8	Samsung HC10	7	85.7	0.0	14.3	101.0	3.3	e*
9	Micros 60	56	94.6	0.0	5.4	97.4	1.9	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Hematocrit




QUALAB tolerance : 9 %

Hematocrit (l/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Automat	5	100.0	0.0	0.0	0.27	4.1	e*
2	Sysmex X	59	100.0	0.0	0.0	0.28	2.7	e

8 additional results were submitted but not published because the method groups were too small. (< results per group)


Hematocrit



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	137	97.8	0.0	2.2	0.28	2.2	e
2	Sysmex KX21	91	98.9	0.0	1.1	0.27	2.6	e
3	Sysmex Poch - 100i	180	95.5	1.7	2.8	0.28	3.1	e
4	Sysmex XP 300	580	98.6	0.7	0.7	0.27	2.2	e
5	Mythic	221	99.1	0.9	0.0	0.27	3.5	e
6	Swelab	28	96.4	3.6	0.0	0.28	4.3	e
7	Celltac Alpha (Nihon	52	92.3	1.9	5.8	0.28	3.6	e
8	Samsung HC10	7	85.7	0.0	14.3	0.29	3.7	e*
9	Micros 60	56	91.0	3.6	5.4	0.26	4.3	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Erythrocytes




QUALAB tolerance : 25 %

Erythrocytes (T/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Automat	6	100.0	0.0	0.0	3.39	3.0	e
2	Sysmex X	59	100.0	0.0	0.0	3.28	3.1	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)


Erythrocytes



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	137	99.3	0.7	0.0	3.44	4.5	e
2	Sysmex KX21	91	98.9	0.0	1.1	3.34	3.4	e
3	Sysmex PochH - 100i	179	97.2	0.6	2.2	3.41	3.2	e
4	Sysmex XP 300	580	98.8	0.2	1.0	3.33	2.6	e
5	Mythic	221	99.5	0.0	0.5	3.29	3.3	e
6	Swelab	28	100.0	0.0	0.0	3.33	3.3	e
7	Celltac Alpha (Nihon	52	94.2	0.0	5.8	3.40	3.2	e
8	Samsung HC10	7	85.7	14.3	0.0	3.35	11.3	e*
9	Micros 60	56	94.6	0.0	5.4	3.23	3.4	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Leucocytes




QUALAB tolerance : 25 %

Leucocytes (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Automat	5	100.0	0.0	0.0	4.50	5.5	e
2	Microscopic	4	100.0	0.0	0.0	4.65	13.3	e*
3	Sysmex X	59	98.3	0.0	1.7	5.28	8.8	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)


Leucocytes



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	137	99.3	0.0	0.7	4.92	3.5	e
2	Sysmex KX21	91	98.9	1.1	0.0	4.84	5.7	e
3	Sysmex Poch - 100i	180	98.3	1.1	0.6	4.59	6.5	e
4	Sysmex XP 300	579	99.1	0.2	0.7	4.76	4.6	e
5	Mythic	221	99.1	0.0	0.9	4.70	6.9	e
6	Swelab	28	92.9	0.0	7.1	4.97	5.5	e
7	Celltac Alpha (Nihon	52	96.2	1.9	1.9	5.05	6.3	e
8	Samsung HC10	7	85.7	0.0	14.3	4.85	11.5	e*
9	Micros 60	56	96.4	3.6	0.0	4.67	8.2	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Thrombocytes




QUALAB tolerance : 25 %

Thrombocytes (G/l)

No. Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Automat	5	100.0	0.0	0.0	202.0	5.7	e
2	Sysmex X	59	98.3	0.0	1.7	190.2	4.9	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)


Thrombocytes



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	137	100.0	0.0	0.0	189.2	4.9	e
2	Sysmex KX21	91	98.9	0.0	1.1	203.8	6.8	e
3	Sysmex Poch - 100i	180	98.9	1.1	0.0	201.9	6.1	e
4	Sysmex XP 300	580	99.0	0.3	0.7	204.7	5.2	e
5	Mythic	222	98.2	0.9	0.9	206.6	8.0	e
6	Swelab	28	96.4	0.0	3.6	194.0	6.9	e
7	Celltac Alpha (Nihon	52	98.1	0.0	1.9	190.5	6.2	e
8	Samsung HC10	7	100.0	0.0	0.0	233.0	8.0	e*
9	Micros 60	56	96.4	1.8	1.8	198.7	9.0	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)


Hemoglobin H2



QUALAB tolerance : 9 %

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Microsemi	908	96.3	1.1	2.6	93.7	2.3	e
2	Abx Micros	38	92.1	5.3	2.6	92.6	3.8	e
3	Z3	241	98.4	0.8	0.8	93.9	3.1	e
4	MEK-1303/5	39	94.8	2.6	2.6	95.4	3.1	e


Hematocrit H2



QUALAB tolerance : 9 %

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Microsemi	908	95.6	1.3	3.1	0.25	3.0	e
2	Abx Micros	38	94.8	2.6	2.6	0.25	3.9	e
3	Z3	242	97.1	1.7	1.2	0.26	3.8	e
4	MEK-1303/5	39	92.3	5.1	2.6	0.30	4.1	e

Leucocytes H2




QUALAB tolerance : 25 %

Leucocytes H2 (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Microsemi	908	98.5	0.4	1.1	4.80	5.5	e
2	Abx Micros	38	100.0	0.0	0.0	4.75	5.0	e
3	Z3	242	99.6	0.4	0.0	4.63	5.6	e
4	MEK-1303/5	39	100.0	0.0	0.0	4.84	4.8	e

Thrombocytes H2




QUALAB tolerance : 25 %

Thrombocytes H2 (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Microsemi	906	98.3	0.7	1.0	189.7	6.4	e
2	Abx Micros	38	100.0	0.0	0.0	189.6	8.0	e
3	Z3	242	99.2	0.4	0.4	210.8	7.1	e
4	MEK-1303/5	39	100.0	0.0	0.0	203.0	5.8	e

Erythrocytes H2




QUALAB tolerance : 25 %

Erythrocytes H2 (T/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Microsemi	907	97.1	0.9	2.0	3.08	4.6	e
2	Abx Micros	38	97.4	2.6	0.0	3.11	6.3	e
3	Z3	242	97.5	0.0	2.5	3.09	3.3	e
4	MEK-1303/5	39	100.0	0.0	0.0	3.24	4.0	e


CRP H2



QUALAB tolerance : 21 %


No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Microsemi	892	93.9	2.2	3.9	69.1	8.9	e
2	Abx Micros	11	100.0	0.0	0.0	71.8	3.7	e
3	ABX Micros CRP200	24	91.7	0.0	8.3	67.0	8.8	e
4	Z3	222	94.1	2.7	3.2	56.8	9.9	e
5	MEK-1303/5	35	85.7	5.7	8.6	61.3	10.7	e

Hemoglobin BG



No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 iStat	14	100.0	0.0	0.0	119.0	3.7	e

Hematocrit




QUALAB tolerance : 9 %

Hematocrit (l/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat	19	100.0	0.0	0.0	0.35	3.2	e
2	EPOC	15	93.3	0.0	6.7	0.35	2.5	e

Hemoglobin




QUALAB tolerance : 9 %

Hemoglobin (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	116	100.0	0.0	0.0	136.3	1.2	e
2	Beckman	7	100.0	0.0	0.0	136.0	1.2	e
3	Yumizen/Pentra	13	100.0	0.0	0.0	137.9	1.7	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Hematocrit




QUALAB tolerance : 9 %

Hematocrit (l/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	118	95.0	2.5	2.5	0.42	3.1	e
2	Beckman	7	100.0	0.0	0.0	0.41	2.1	e
3	Yumizen/Pentra	13	100.0	0.0	0.0	0.40	2.5	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Erythrocytes




QUALAB tolerance : 25 %

Erythrocytes (T/l)

No. Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	118	100.0	0.0	0.0	4.74	2.4	e
2	Beckman	7	100.0	0.0	0.0	4.75	1.0	e
3	Yumizen/Pentra	13	100.0	0.0	0.0	4.70	1.7	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Leucocytes




QUALAB tolerance : 25 %

Leucocytes (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	117	100.0	0.0	0.0	6.42	6.5	e
2	Beckman	7	100.0	0.0	0.0	5.70	17.3	a
3	Yumizen/Pentra	13	92.3	0.0	7.7	5.32	14.5	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Thrombocytes




QUALAB tolerance : 25 %

Thrombocytes (G/l)

No. Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	116	99.1	0.9	0.0	239.4	6.8	e
2	Beckman	7	100.0	0.0	0.0	229.5	2.8	e
3	Yumizen/Pentra	13	100.0	0.0	0.0	224.5	13.1	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Neutrophils




MQ tolerance : 25 %

Neutrophils (G/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	118	98.4	0.8	0.8	3.77	8.0	e
2	Beckman	7	71.4	14.3	14.3	4.30	16.8	e*
3	Yumizen/Pentra	12	75.0	16.7	8.3	2.53	21.2	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Lymphocytes




MQ tolerance : 25 %

Lymphocytes (G/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	118	100.0	0.0	0.0	2.02	6.0	e
2	Beckman	7	100.0	0.0	0.0	1.89	10.8	e*
3	Yumizen/Pentra	12	91.7	0.0	8.3	2.13	13.3	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Monocytes




MQ tolerance : 80 %

Monocytes (G/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	118	100.0	0.0	0.0	0.48	18.1	e
2	Beckman	7	100.0	0.0	0.0	0.40	44.0	e*
3	Yumizen/Pentra	12	91.7	0.0	8.3	0.33	37.4	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Eosinophils




MQ tolerance : 80 %

Eosinophils (G/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	117	99.1	0.9	0.0	0.07	27.5	a
2	Beckman	7	85.7	14.3	0.0	0.10	43.4	e*
3	Yumizen/Pentra	12	100.0	0.0	0.0	0.06	45.4	a

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Basophiles




MQ tolerance : 80 %
(< 0.10: +/- 0.08 G/l)

Basophiles (G/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	116	92.3	4.3	3.4	0.09	61.4	a
2	Beckman	7	85.7	0.0	14.3	0.01	7.9	e
3	Yumizen/Pentra	12	91.7	0.0	8.3	0.04	72.7	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

MCV




MQ tolerance : 25 %

MCV (fl)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	106	100.0	0.0	0.0	87.8	3.4	e
2	Beckman	5	100.0	0.0	0.0	86.6	2.1	e
3	Yumizen/Pentra	9	100.0	0.0	0.0	84.3	2.9	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

MCH




MQ tolerance : 25 %

MCH (pg)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	107	100.0	0.0	0.0	28.7	1.5	e
2	Beckman	5	100.0	0.0	0.0	28.5	1.1	e
3	Yumizen/Pentra	10	100.0	0.0	0.0	29.5	2.4	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

MCHC




MQ tolerance : 25 %

MCHC (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	108	100.0	0.0	0.0	327	3.7	e
2	Beckman	5	100.0	0.0	0.0	328	1.4	e
3	Yumizen/Pentra	10	100.0	0.0	0.0	350	4.3	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

RDW




MQ tolerance : 25 %

RDW (%)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	102	100.0	0.0	0.0	13.8	2.8	e
2	Beckman	5	100.0	0.0	0.0	14.1	5.0	e
3	Yumizen/Pentra	10	100.0	0.0	0.0	14.0	8.3	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Immature Granulocytes




MQ tolerance : 25 %
(< 0.10: +/- 0.10 G/l)

Immature Granulocytes (G/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	101	98.0	0.0	2.0	0.07	51.6	a

Reticulocytes




MQ tolerance : 30 %

Reticulocytes (G/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	65	100.0	0.0	0.0	49.3	12.2	a
2	Beckman	6	100.0	0.0	0.0	29.6	7.8	a

One result was submitted but not published because the method group was too small. (< 4 results per group)

Hämolyseindex Probe A




MQ tolerance : 30 % Hämolyseindex Probe A (Index (mg/))
 (< 20.00: +/- 8.00 Index (mg/))

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	22	100.0	0.0	0.0	7.32	44.9	e*
2	Abbott	8	100.0	0.0	0.0	5.00	35.1	e*

One result was submitted but not published because the method group was too small. (< 4 results per group)

Hämolyseindex Probe B




MQ tolerance : 30 % Hämolyseindex Probe B (Index (mg/))
 (< 20.00: +/- 8.00 Index (mg/))

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	17	100.0	0.0	0.0	0.15	311.1	e*
2	Abbott	7	85.7	14.3	0.0	2.00	101.9	e*


One result was submitted but not published because the method group was too small. (< 4 results per group)

Lipemia index A



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	9	100.0	0.0	0.0	23.00	45.8	a
2	Abbott	7	100.0	0.0	0.0	26.57	51.2	a

Lipemia index B




MQ tolerance : 30 %

Lipemia index B (Index (mg/))


No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	9	100.0	0.0	0.0	18.00	44.5	a
2	Abbott	7	100.0	0.0	0.0	39.86	65.6	a

Icteria Index A



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	9	100.0	0.0	0.0	17.00	13.3	e*
2	Abbott	7	100.0	0.0	0.0	22.92	11.9	e*

Icteria Index B




MQ tolerance : 30 %
(< 5.00: +/- 1.50 Index (mg/))

Icteria Index B (Index (mg/))

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	7	100.0	0.0	0.0	0.01	0.0	e
2	Abbott	7	100.0	0.0	0.0	0.58	56.8	e*

Erythrocyte sedimentation rate 1h




MQ tolerance : 40 %

Erythrocyte sedimentation rate 1h (mm/h)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	MINI-CUBE	29	93.1	6.9	0.0	14	34.2	a
2	miniiSed	11	90.9	0.0	9.1	1	0.0	a
3	Sarstedt Sedivette	17	82.4	17.6	0.0	11	34.3	a
4	Sarstedt Microvette	4	75.0	0.0	25.0	13	17.8	a
5	BD Seditainer	43	90.6	4.7	4.7	10	22.5	a
6	Other methods	22	95.5	0.0	4.5	11	21.2	a

Erythrocyte sedimentation rate 2h




MQ tolerance : 40 %

Erythrocyte sedimentation rate 2h (mm/2h)


No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sarstedt Sedivette	7	100.0	0.0	0.0	24	12.3	a
2	BD Seditainer	4	100.0	0.0	0.0	21	13.2	a
3	Other methods	4	100.0	0.0	0.0	22	12.9	a

Hemoglobin HS



No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	23	95.7	0.0	4.3	152.7	3.8	e

Hematocrit HS




MQ tolerance : 9 %

Hematocrit HS (l/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	23	91.4	4.3	4.3	0.4	3.6	e

Erythrocytes HS




MQ tolerance : 25 %

Erythrocytes HS (T/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	23	91.4	4.3	4.3	4.58	7.8	e

Leucocytes HS




MQ tolerance : 25 %

Leucocytes HS (G/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	23	95.7	4.3	0.0	7.62	10.2	e

Trombocytes HS




MQ tolerance : 25 %

Trombocytes HS (G/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	23	91.4	4.3	4.3	273.7	8.7	e

Leucocytes BF




MQ tolerance : 40 %


Leucocytes BF (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	13	100.0	0.0	0.0	0.190	3.7	e


Erythrocytes BF



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	12	100.0	0.0	0.0	53.667	4.5	e

Total cells (TC)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	10	100.0	0.0	0.0	0.197	9.3	e


Mononuclear cells (MN)

MQ tolerance : 40 %

Mononuclear cells (MN) (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	11	100.0	0.0	0.0	0.062	9.8	e

Polynuclear cells (PMN)




MQ tolerance : 40 %

Polynuclear cells (PMN) (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	11	100.0	0.0	0.0	0.143	11.9	a


CRP



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Autolyser	10	90.0	0.0	10.0	52.2	5.6	e
2	Cobas b101	404	99.5	0.0	0.5	46.8	4.6	e
3	Siemens	7	100.0	0.0	0.0	50.0	3.3	e
4	Cobas	42	95.2	2.4	2.4	50.8	5.9	e
5	Afinion	1083	99.3	0.2	0.5	51.3	4.4	e
6	NycoCard SingleTest-	53	81.2	7.5	11.3	50.2	12.6	e
7	Quick Read go	84	100.0	0.0	0.0	54.6	8.6	e
8	Eurolyser	61	78.7	8.2	13.1	59.9	13.9	e
9	Fuji Dri-Chem	14	92.9	7.1	0.0	56.1	10.8	e*
10	Piccolo	6	66.7	0.0	33.3	66.7	6.6	e*
11	Celltac chemi	19	94.7	0.0	5.3	52.6	5.4	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)


CRP



QUALAB tolerance : 21 %

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	QuikRead (Vollblut)	14	92.9	7.1	0.0	89.1	10.0	e*

CRP




QUALAB tolerance : 21 %

CRP (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Spinit	8	100.0	0.0	0.0	46.2	3.7	e
2	Abbott	15	100.0	0.0	0.0	52.7	3.2	e
3	Beckman	5	80.0	0.0	20.0	57.0	4.2	e
4	AQT 90 FLEX	7	100.0	0.0	0.0	54.0	2.1	e
5	Spotchem D-Concept	6	100.0	0.0	0.0	51.9	9.0	e*


One result was submitted but not published because the method group was too small. (< 4 results per group)

IgG



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	21	100.0	0.0	0.0	18.42	4.4	e
2	Nephelometry	5	100.0	0.0	0.0	17.70	5.3	e*
3	Other methods	6	100.0	0.0	0.0	18.30	6.0	e*


IgA



QUALAB tolerance : 15 %

No. Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	19	94.7	5.3	0.0	3.46	6.4	e
2	Nephelometry	6	83.3	0.0	16.7	3.75	3.4	e
3	Other methods	6	100.0	0.0	0.0	3.37	2.7	e


IgM



QUALAB tolerance : 15 %


No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	22	95.5	0.0	4.5	1.69	4.3	e
2	Nephelometry	8	100.0	0.0	0.0	1.78	5.6	e*

IgE



No. Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	5	100.0	0.0	0.0	151	10.9	a
2	Cobas	6	100.0	0.0	0.0	214	3.6	e

Alpha-1-Antitrypsin




MQ tolerance : 25 %

Alpha-1-Antitrypsin (g/l)


No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Nephelometry	4	100.0	0.0	0.0	2.06	5.3	e
2	all Participants	9	100.0	0.0	0.0	1.82	7.1	a

Anti-Streptolysin-Antibodies



No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	12	100.0	0.0	0.0	253	9.6	e
2	Other methods	5	100.0	0.0	0.0	190	1.2	a

Complement C3




QUALAB tolerance : 15 %

Complement C3 (g/l)


No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	19	94.7	0.0	5.3	2.60	4.2	e
2 additional results were submitted but not published because the method groups were too small. (< results per group)								

Complement C4



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Alinity	5	100.0	0.0	0.0	0.51	3.2	e
2	Other methods	15	100.0	0.0	0.0	0.50	6.9	e


Haptoglobin



MQ tolerance : 25 %

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	29	100.0	0.0	0.0	2.36	2.9	e

Transferrin




MQ tolerance : 25 %

Transferrin (g/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	38	100.0	0.0	0.0	3.46	3.4	e


Beta-2 microglobuline



MQ tolerance : 25 % Beta-2 microglobuline (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	12	100.0	0.0	0.0	3.14	5.1	e
2 additional results were submitted but not published because the method groups were too small. (< results per group)								

Rheumatoid factor




MQ tolerance : 25 %

Rheumatoid factor (U/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	7	100.0	0.0	0.0	45.0	3.9	e
2	Other methods	8	100.0	0.0	0.0	40.5	2.9	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Ceruloplasmin




MQ tolerance : 25 %

Ceruloplasmin (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens	9	100.0	0.0	0.0	510.00	3.7	e
2	Other methods	4	100.0	0.0	0.0	390.50	5.0	a

Prealbumin




MQ tolerance : 25 %

Prealbumin (mg/l)


No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	19	100.0	0.0	0.0	321.08	7.4	e

Soluble transferrin receptor



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	14	100.0	0.0	0.0	5.0	2.4	e
3 additional results were submitted but not published because the method groups were too small. (< results per group)								

free light chain kappa




QUALAB tolerance : 20 %

free light chain kappa (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	N Latex	6	100.0	0.0	0.0	11.90	8.7	e*
2	Freelite	12	100.0	0.0	0.0	22.99	6.1	e


free light chain lambda



QUALAB tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	N Latex	6	100.0	0.0	0.0	9.03	5.4	e
2	Freelite	12	100.0	0.0	0.0	19.88	3.2	e

IgE peanut qn




MQ tolerance : 30 %

IgE peanut qn (kU/L)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	13	100.0	0.0	0.0	2.96	12.8	e

IgE birch qn




QUALAB tolerance : 30 %

IgE birch qn (kU/L)


No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	14	100.0	0.0	0.0	46.84	11.9	e

IgE cat qn



No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	13	100.0	0.0	0.0	4.96	6.7	e


IgE total



QUALAB tolerance : 30 % IgE total (kU/L)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	13	100.0	0.0	0.0	259	7.0	e
One result was submitted but not published because the method group was too small. (< 4 results per group)								


IgE sx1 qn



MQ tolerance : 30 %

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	9	77.8	22.2	0.0	68.80	22.1	e*


IgE fx5 qn



MQ tolerance : 30 %
(< 1.50: +/- 0.45 kU/L)


No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	9	100.0	0.0	0.0	0.81	17.2	e*

IgE rx1qn




No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	100.0	0.0	0.0	53.25	10.2	e*

IgE rx2 qn




No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	100.0	0.0	0.0	3.53	10.5	e*

IgE D. pteronyssinus qn



No.Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 all Participants	13	100.0	0.0	0.0	1.67	13.2	e*

CRP HS




QUALAB tolerance : 21 %
(< 10.00: +/- 2.00 mg/l)

CRP HS (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	10	100.0	0.0	0.0	3.35	10.1	e*

One result was submitted but not published because the method group was too small. (< 4 results per group)

Lipoprotein (a)




MQ tolerance : 25 %

Lipoprotein (a) (nmol/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	6	100.0	0.0	0.0	38	8.3	e*
2	Others	5	100.0	0.0	0.0	50	2.8	e


CRP



QUALAB tolerance : 21 %

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS	186	91.9	1.6	6.5	78.2	8.3	e

Anti deam. Gliadin IgG




MQ tolerance : 30 %

Anti deam. Gliadin IgG (U/ml)

No.Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 Phadia	6	100.0	0.0	0.0	2.20	11.7	e*
3 additional results were submitted but not published because the method groups were too small. (< results per group)							

Anti deam. Gliadin IgA




MQ tolerance : 30 %

Anti deam. Gliadin IgA (U/ml)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	4	100.0	0.0	0.0	3.65	5.7	e
2	Phadia	4	100.0	0.0	0.0	2.80	22.4	a

Anti tTG IgG




MQ tolerance : 30 %

Anti tTG IgG (U/ml)


No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	4	100.0	0.0	0.0	36.50	11.0	e*

Anti tTG IgA



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	7	100.0	0.0	0.0	108.00	16.3	e*
2 additional results were submitted but not published because the method groups were too small. (< results per group)								

CRP Lumira




QUALAB tolerance : 21 %

CRP Lumira (mg/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Lumira Dx	8	87.5	0.0	12.5	78.0	7.3	e*

Albumine




QUALAB tolerance : 12 %

Albumine (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	4	100.0	0.0	0.0	36.8	2.6	e
2	Abbott	12	100.0	0.0	0.0	39.1	1.7	e
3	Beckman	4	100.0	0.0	0.0	38.6	2.4	e
4	Roche	36	100.0	0.0	0.0	40.3	2.7	e
5	Autolyser	8	100.0	0.0	0.0	39.3	3.6	e
6	Selectra Pro	11	100.0	0.0	0.0	38.2	3.2	e
7	Fuji Dri-Chem	250	99.2	0.8	0.0	47.0	4.2	e
8	Spotchem D-Concept	234	97.8	0.9	1.3	47.4	5.4	e
9	Spotchem SP-4430	29	96.6	0.0	3.4	44.1	5.9	e
10	Piccolo	57	98.2	0.0	1.8	41.2	3.1	e
11	Skyla	4	100.0	0.0	0.0	44.0	1.1	e
12	Hitachi S40/M40	4	100.0	0.0	0.0	36.1	2.3	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)


Alkaline phosphatase



No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	15	100.0	0.0	0.0	257	1.7	e
2	Beckman	5	100.0	0.0	0.0	274	2.0	e
3	Roche	36	97.2	0.0	2.8	226	6.0	e
4	Siemens	6	100.0	0.0	0.0	227	3.0	e
5	Autolyser	20	95.0	5.0	0.0	243	7.9	e
6	Selectra Pro	15	93.3	6.7	0.0	283	7.9	e
7	Fuji Dri-Chem	1027	99.4	0.3	0.3	211	5.5	e
8	Spotchem D-Concept	556	98.2	0.5	1.3	190	5.5	e
9	Spotchem SP-4430	81	93.9	4.9	1.2	207	7.7	e
10	Piccolo	49	98.0	0.0	2.0	262	2.6	e
11	Skylla	5	100.0	0.0	0.0	262	7.0	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)


Amylase



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	10	100.0	0.0	0.0	233	3.1	e
2	Beckman	4	100.0	0.0	0.0	229	1.9	e
3	Roche	14	100.0	0.0	0.0	213	2.5	e
4	Autolyser	7	100.0	0.0	0.0	198	5.9	e*
5	Selectra Pro	10	100.0	0.0	0.0	257	2.8	e
6	Fuji Dri-Chem	745	99.0	0.5	0.5	209	4.0	e
7	Spotchem D-Concept	405	98.8	0.2	1.0	248	5.6	e
8	Spotchem SP-4430	63	95.2	3.2	1.6	246	7.1	e
9	Piccolo	52	100.0	0.0	0.0	185	2.9	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Pancreatic amylase




QUALAB tolerance : 18 %

Pancreatic amylase (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	14	100.0	0.0	0.0	176	1.7	e
2	Roche	17	100.0	0.0	0.0	176	2.1	e
3	Autolyser	11	100.0	0.0	0.0	169	3.6	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)


Bilirubin



No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	16	100.0	0.0	0.0	80.0	5.7	e
2	Beckman	6	100.0	0.0	0.0	90.5	5.4	e*
3	Roche	35	100.0	0.0	0.0	78.3	3.8	e
4	Siemens	5	100.0	0.0	0.0	91.7	3.9	e
5	Autolyser	17	100.0	0.0	0.0	88.0	4.5	e
6	Selectra Pro	17	88.2	5.9	5.9	81.6	8.3	e
7	Fuji Dri-Chem	833	99.8	0.1	0.1	80.2	5.1	e
8	Spotchem D-Concept	446	98.7	0.9	0.4	80.3	4.9	e
9	Spotchem SP-4430	77	97.4	1.3	1.3	84.8	5.6	e
10	Piccolo	54	96.2	1.9	1.9	81.2	5.9	e
11	Skyla	5	100.0	0.0	0.0	97.0	5.2	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Bilirubin direct




MQ tolerance : 18 %

Bilirubin direct (μmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Autolyser	10	100.0	0.0	0.0	39.9	8.3	e*
2	Fuji Dri-Chem	24	91.7	8.3	0.0	41.7	9.4	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)


Calcium



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	18	100.0	0.0	0.0	2.88	1.5	e
2	Beckman	5	100.0	0.0	0.0	2.96	2.0	e
3	Roche	37	100.0	0.0	0.0	2.89	1.8	e
4	Siemens	4	100.0	0.0	0.0	2.89	2.4	e*
5	Autolyser	9	100.0	0.0	0.0	2.79	3.9	e*
6	Fuji Dri-Chem	273	96.0	2.9	1.1	3.06	3.9	e
7	Spotchem D-Concept	77	87.0	9.1	3.9	2.26	5.2	e
8	Spotchem SP-4430	12	91.7	0.0	8.3	2.61	4.5	e*
9	Piccolo	48	100.0	0.0	0.0	2.89	2.2	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Calcium ISE




MQ tolerance : 12 %

Calcium ISE (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat Chem8	12	100.0	0.0	0.0	1.13	2.9	e
2 additional results were submitted but not published because the method groups were too small. (< results per group)								


Chloride



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	20	90.0	10.0	0.0	110	2.9	e
2	Beckman	5	100.0	0.0	0.0	106	1.4	e
3	Roche	27	96.3	3.7	0.0	107	1.9	e
4	Siemens	4	100.0	0.0	0.0	111	1.4	e
5	Fuji Dri-Chem	941	98.5	1.3	0.2	110	1.9	e
6	Spotchem D-Concept	354	98.9	0.3	0.8	117	1.5	e
7	Spotchem EL-SE 1520	56	91.0	5.4	3.6	122	2.7	e
8	Piccolo	27	100.0	0.0	0.0	109	2.4	e
9	Exias	11	100.0	0.0	0.0	112	1.6	e
10	iStat Chem8	11	100.0	0.0	0.0	116	0.9	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)


Cholesterol total



No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	19	100.0	0.0	0.0	5.63	1.6	e
2	Beckman	4	100.0	0.0	0.0	5.92	3.0	e*
3	Roche	30	100.0	0.0	0.0	5.58	2.5	e
4	Autolyser	20	100.0	0.0	0.0	5.60	3.2	e
5	Selectra Pro	15	93.3	0.0	6.7	5.69	4.7	e*
6	Fuji Dri-Chem	980	97.2	1.3	1.5	5.44	3.9	e
7	Spotchem D-Concept	471	97.3	0.6	2.1	5.23	3.3	e
8	Spotchem SP-4430	81	93.8	3.7	2.5	5.14	4.0	e
9	Piccolo	25	100.0	0.0	0.0	5.57	1.6	e
10	Reflotron	4	75.0	25.0	0.0	5.15	9.0	e*
11	Cholestech LDX	273	95.6	1.8	2.6	5.46	4.2	e
12	Other methods	4	100.0	0.0	0.0	5.01	0.3	e

9 additional results were submitted but not published because the method groups were too small. (< results per group)


Cholesterin HDL



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	14	100.0	0.0	0.0	1.45	2.7	e
2	Beckman	6	100.0	0.0	0.0	1.50	5.0	e
3	Roche	28	100.0	0.0	0.0	1.09	3.2	e
4	Siemens	5	100.0	0.0	0.0	1.33	8.0	e*
5	Autolyser	20	100.0	0.0	0.0	1.30	6.1	e
6	Selectra Pro	14	100.0	0.0	0.0	1.27	7.7	e
7	Fuji Dri-Chem	947	99.5	0.0	0.5	1.27	3.3	e
8	Spotchem D-Concept	454	98.0	1.1	0.9	0.99	8.1	e
9	Spotchem SP-4430	72	93.0	2.8	4.2	0.91	9.3	e
10	Piccolo	24	87.5	0.0	12.5	1.08	5.6	e
11	Cholestech LDX	273	96.0	1.8	2.2	1.05	8.3	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Creatine kinase




QUALAB tolerance : 18 %

Creatine kinase (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	16	100.0	0.0	0.0	455	2.1	e
2	Beckman	5	100.0	0.0	0.0	459	2.3	e
3	Roche	33	100.0	0.0	0.0	434	2.0	e
4	Siemens	6	100.0	0.0	0.0	433	5.5	e*
5	Autolyser	17	100.0	0.0	0.0	459	3.6	e
6	Selectra Pro	9	100.0	0.0	0.0	435	5.9	e
7	Fuji Dri-Chem	669	98.4	1.3	0.3	481	4.7	e
8	Spotchem D-Concept	323	99.1	0.0	0.9	391	6.2	e
9	Spotchem SP-4430	39	94.9	0.0	5.1	429	3.9	e
10	Piccolo	17	100.0	0.0	0.0	424	2.8	e

One result was submitted but not published because the method group was too small. (< 4 results per group)


Cholesterol LDL



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	16	100.0	0.0	0.0	3.6	2.9	e
2	Beckman	4	100.0	0.0	0.0	3.7	0.7	e
3	Roche, Cobas	18	100.0	0.0	0.0	3.5	2.8	e
4	Autolyser	10	100.0	0.0	0.0	3.5	8.0	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)


Iron



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	14	100.0	0.0	0.0	38	3.0	e
2	Roche	21	100.0	0.0	0.0	37	1.6	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Gamma-glutamyltransferase




QUALAB tolerance : 18 %

Gamma-glutamyltransferase (U/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	16	100.0	0.0	0.0	122	3.6	e
2	Beckman	6	100.0	0.0	0.0	113	1.7	e
3	Cobas	37	100.0	0.0	0.0	111	6.6	e
4	Siemens	6	100.0	0.0	0.0	120	6.1	e*
5	Autolyser	20	100.0	0.0	0.0	108	4.6	e
6	Selectra Pro	16	100.0	0.0	0.0	115	4.2	e
7	Fuji Dri-Chem	1138	99.6	0.0	0.4	135	5.0	e
8	Spotchem D-Concept	625	98.6	0.6	0.8	138	7.0	e
9	Spotchem SP-4430	131	97.7	1.5	0.8	141	7.9	e
10	Piccolo	57	100.0	0.0	0.0	101	3.3	e
11	Skyla	5	100.0	0.0	0.0	108	1.2	e
12	Reflotron	4	75.0	25.0	0.0	135	14.2	e*

One result was submitted but not published because the method group was too small. (< 4 results per group)


Glucose



No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	17	100.0	0.0	0.0	14.1	1.6	e
2	Beckman	6	100.0	0.0	0.0	14.3	1.9	e
3	Roche	38	100.0	0.0	0.0	14.1	1.7	e
4	Siemens	5	100.0	0.0	0.0	14.0	2.5	e*
5	Autolyser	18	88.8	5.6	5.6	13.5	4.9	e*
6	Selectra Pro	17	82.3	11.8	5.9	14.0	4.8	e*
7	Fuji Dri-Chem	1078	99.6	0.2	0.2	12.7	2.5	e
8	Spotchem D-Concept	585	93.7	4.4	1.9	13.3	4.4	e
9	Spotchem SP-4430	107	80.4	13.1	6.5	14.2	5.8	e
10	Piccolo	70	100.0	0.0	0.0	13.8	0.9	e
11	Reflotron	4	75.0	0.0	25.0	14.1	1.1	e
12	Cholestech LDX	267	86.9	8.6	4.5	13.5	5.1	e
13	iStat Chem8	12	100.0	0.0	0.0	12.6	2.5	e
14	Cobas Pulse	41	100.0	0.0	0.0	13.1	2.1	e

3 additional results were submitted but not published because the participant groups were too small. (< results per group)

Glucose




QUALAB tolerance : 9 %

Glucose (mmol/l)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Accu-Chek Instant	139	99.3	0.0	0.7	13.0	3.2	e
2	Accu-Chek Aviva	107	88.8	4.7	6.5	15.0	3.7	e
3	Accu-Chek Inform 2	950	98.4	1.2	0.4	15.9	3.2	e
4	Accu-Check Guide	344	97.6	1.2	1.2	13.0	3.1	e
5	Contour XT	1406	96.3	2.0	1.7	13.8	3.4	e
6	Skyla	5	100.0	0.0	0.0	14.6	0.8	e
7	Statstrip/Xpress	89	100.0	0.0	0.0	11.9	3.9	e
8	Glucocard	9	77.8	0.0	22.2	21.9	4.3	e*
9	Hemocue 201+ P-equiv	147	97.3	2.0	0.7	14.9	3.0	e
10	Hemocue 201RT P-equiv	131	100.0	0.0	0.0	14.9	1.9	e
11	CardioChek	4	25.0	0.0	75.0	14.1	0.0	a
12	Freestyle Freedom li	4	100.0	0.0	0.0	15.6	4.2	e*
13	Contour NEXT	47	93.6	0.0	6.4	13.4	3.2	e


5 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose B



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OneTouch Verio	28	96.4	3.6	0.0	14.0	4.4	e
2	Contour 2 (5s)	8	87.5	0.0	12.5	11.6	5.1	e*
3	Healthpro	21	90.5	9.5	0.0	23.4	5.5	e*
4	Mylife UNIO	387	100.0	0.0	0.0	16.4	3.2	e
5	mylife Pura	85	88.2	2.4	9.4	17.3	4.4	e
6	Alpha Check	26	80.8	15.4	3.8	20.2	6.9	e*


Uric Acid



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	18	94.4	5.6	0.0	479	3.8	e
2	Beckman	6	100.0	0.0	0.0	492	2.0	e
3	Roche	33	100.0	0.0	0.0	475	2.4	e
4	Siemens	4	100.0	0.0	0.0	481	3.4	e*
5	Autolyser	18	94.4	0.0	5.6	498	4.3	e
6	Selectra Pro	17	100.0	0.0	0.0	488	3.8	e
7	Fuji Dri-Chem	1053	98.5	0.6	0.9	521	2.7	e
8	Spotchem D-Concept	588	98.4	0.9	0.7	450	3.7	e
9	Spotchem SP-4430	105	98.0	1.0	1.0	416	4.4	e
10	Piccolo	34	94.2	2.9	2.9	423	5.3	e
11	Skylla	5	100.0	0.0	0.0	487	1.1	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Urea




QUALAB tolerance : 15 %

Urea (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	16	100.0	0.0	0.0	20.4	3.4	e
2	Beckman	6	100.0	0.0	0.0	19.9	6.9	e*
3	Roche	35	100.0	0.0	0.0	19.7	2.5	e
4	Siemens	6	100.0	0.0	0.0	20.5	2.7	e
5	Autolyser	15	100.0	0.0	0.0	20.5	4.5	e
6	Selectra Pro	13	84.6	15.4	0.0	19.7	7.7	e*
7	Fuji Dri-Chem	629	99.7	0.0	0.3	20.8	2.1	e
8	Spotchem D-Concept	331	91.3	6.3	2.4	18.7	8.2	e
9	Spotchem SP-4430	56	92.9	7.1	0.0	19.0	7.8	e
10	Piccolo	62	100.0	0.0	0.0	19.7	2.5	e
11	Skylla	5	100.0	0.0	0.0	21.7	2.1	e
12	iStat Chem8	9	100.0	0.0	0.0	26.1	2.1	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)


Potassium



No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	17	100.0	0.0	0.0	5.88	0.6	e
2	Beckman	6	100.0	0.0	0.0	5.88	1.4	e
3	Roche	37	100.0	0.0	0.0	5.96	1.4	e
4	Siemens	4	100.0	0.0	0.0	5.95	3.7	e*
5	Autolyser	20	95.0	0.0	5.0	5.93	2.3	e
6	Fuji Dri-Chem	1110	98.9	0.6	0.5	5.91	1.6	e
7	Spotchem D-Concept	466	98.1	0.2	1.7	5.39	1.5	e
8	Spotchem EL-SE 1520	73	100.0	0.0	0.0	5.36	2.0	e
9	Piccolo	39	76.9	15.4	7.7	6.12	4.0	e
10	iStat Chem8	15	100.0	0.0	0.0	5.78	1.8	e
11	Exias	14	100.0	0.0	0.0	5.92	0.7	e


6 additional results were submitted but not published because the method groups were too small. (< results per group)

Creatinine



No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	16	100.0	0.0	0.0	409	1.5	e
2	Beckman	6	100.0	0.0	0.0	407	2.1	e
3	Roche	35	100.0	0.0	0.0	392	5.0	e
4	Siemens	6	100.0	0.0	0.0	404	1.7	e
5	Enzymatic	4	100.0	0.0	0.0	416	3.2	e
6	Autolyser	20	100.0	0.0	0.0	411	4.0	e
7	Selectra Pro	17	100.0	0.0	0.0	401	4.6	e
8	Fuji Dri-Chem	1172	99.4	0.1	0.5	379	4.6	e
9	Spotchem D-Concept	640	99.4	0.0	0.6	360	3.2	e
10	Spotchem SP-4430	147	100.0	0.0	0.0	366	2.4	e
11	Piccolo	65	100.0	0.0	0.0	398	3.5	e
12	Skyla	5	100.0	0.0	0.0	403	7.2	e*
13	Reflotron	7	85.7	0.0	14.3	445	8.7	e*
14	EPOC	11	81.8	0.0	18.2	404	5.7	e

Creatinine E




QUALAB tolerance : 18 %

Creatinine E (μmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat Chem8	44	100.0	0.0	0.0	441	4.2	e
2	ABL700/800	14	100.0	0.0	0.0	403	6.9	e

eGFR CKD-EPI




MQ tolerance : 30 %

eGFR CKD-EPI ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	58	98.3	0.0	1.7	12	8.8	e
2	Reflotron	4	75.0	0.0	25.0	12	17.1	e*
3	Fuji Dri-Chem	407	95.8	1.5	2.7	13	8.1	e
4	Spotchem	281	91.1	3.6	5.3	14	9.4	e

eGFR Cockcroft-Gault




MQ tolerance : 30 %

eGFR Cockcroft-Gault ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Fuji Dri-Chem	31	93.6	3.2	3.2	15	18.4	e
2	Spotchem	14	92.9	0.0	7.1	16	17.0	e*


2 additional results were submitted but not published because the method groups were too small. (< results per group)

LDH

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	18	100.0	0.0	0.0	294	3.5	e
2	Beckman	5	100.0	0.0	0.0	314	4.7	e
3	Roche	34	100.0	0.0	0.0	314	2.4	e
4	Autolyser	7	100.0	0.0	0.0	306	7.4	e*
5	Fuji Dri-Chem	112	92.8	1.8	5.4	264	6.4	e
6	Spotchem D-Concept	42	100.0	0.0	0.0	243	5.8	e
7	Spotchem SP-4430	12	100.0	0.0	0.0	238	8.0	e*

7 additional results were submitted but not published because the method groups were too small. (< results per group)


Magnesium



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	17	100.0	0.0	0.0	1.35	1.5	e
2	Beckman	4	100.0	0.0	0.0	1.39	1.5	e
3	Roche	29	100.0	0.0	0.0	1.39	3.2	e
4	Fuji Dri-Chem	77	92.2	3.9	3.9	1.53	4.6	e
5	Spotchem D-Concept	37	100.0	0.0	0.0	1.15	2.8	e
6	Spotchem SP-4430	4	100.0	0.0	0.0	1.13	6.1	e*

12 additional results were submitted but not published because the method groups were too small. (< results per group)


Sodium



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Autolyser	10	100.0	0.0	0.0	154	1.1	e
2	Abbott	18	100.0	0.0	0.0	150	0.6	e
3	Beckman	6	100.0	0.0	0.0	150	1.0	e
4	Roche	37	100.0	0.0	0.0	150	0.9	e
5	Siemens	4	100.0	0.0	0.0	151	2.8	e*
6	Fuji Dri-Chem	1022	99.0	0.4	0.6	153	1.5	e
7	Spotchem D-Concept	396	98.5	0.5	1.0	146	1.1	e
8	Spotchem EL-SE 1520	63	100.0	0.0	0.0	145	1.2	e
9	Piccolo	36	100.0	0.0	0.0	149	1.2	e
10	Exias	14	100.0	0.0	0.0	150	1.2	e
11	iStat Chem8	15	100.0	0.0	0.0	148	1.2	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)


Phosphate



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	17	100.0	0.0	0.0	1.75	2.4	e
2	Beckman	4	100.0	0.0	0.0	1.80	1.4	e
3	Roche	34	100.0	0.0	0.0	1.76	1.9	e
4	Fuji Dri-Chem	77	96.1	2.6	1.3	1.79	4.7	e
5	Spotchem D-Concept	14	100.0	0.0	0.0	1.81	3.1	e
6	Piccolo	4	100.0	0.0	0.0	2.15	3.6	e*

14 additional results were submitted but not published because the method groups were too small. (< results per group)


Protein total



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	16	100.0	0.0	0.0	62.8	2.3	e
2	Beckman	4	100.0	0.0	0.0	62.8	2.5	e
3	Roche	31	100.0	0.0	0.0	60.9	2.8	e
4	Siemens	4	100.0	0.0	0.0	64.1	5.1	e*
5	Selectra Pro	9	100.0	0.0	0.0	62.0	3.3	e
6	Fuji Dri-Chem	192	100.0	0.0	0.0	57.5	3.4	e
7	Spotchem D-Concept	183	95.7	1.6	2.7	62.0	4.9	e
8	Spotchem SP-4430	25	96.0	4.0	0.0	63.0	4.5	e
9	Piccolo	47	97.9	0.0	2.1	62.0	1.2	e
10	Skyla	5	100.0	0.0	0.0	67.0	1.2	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)


Aspartate aminotransferase



No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	18	100.0	0.0	0.0	190	3.6	e
2	Beckman	5	100.0	0.0	0.0	188	6.1	e*
3	Roche	38	100.0	0.0	0.0	186	4.4	e
4	Siemens	4	100.0	0.0	0.0	178	4.5	e*
5	Autolyser	20	100.0	0.0	0.0	168	5.1	e
6	Selectra Pro	17	100.0	0.0	0.0	181	4.0	e
7	Fuji Dri-Chem	1148	98.9	0.8	0.3	181	4.6	e
8	Spotchem D-Concept	630	98.8	0.2	1.0	157	4.6	e
9	Spotchem SP-4430	140	99.3	0.7	0.0	154	5.5	e
10	Piccolo	71	98.6	0.0	1.4	161	4.7	e
11	Skyla	5	100.0	0.0	0.0	178	3.2	e
12	Reflotron	4	100.0	0.0	0.0	184	11.7	e*

One result was submitted but not published because the method group was too small. (< 4 results per group)


Alanine aminotransferase



No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	16	100.0	0.0	0.0	124	3.7	e
2	Beckman	6	100.0	0.0	0.0	128	3.9	e
3	Roche	38	100.0	0.0	0.0	122	2.9	e
4	Siemens	6	100.0	0.0	0.0	130	2.6	e
5	Autolyser	20	100.0	0.0	0.0	120	3.3	e
6	Selectra Pro	17	100.0	0.0	0.0	124	4.1	e
7	Fuji Dri-Chem	1165	98.5	0.6	0.9	127	5.7	e
8	Spotchem D-Concept	634	98.5	0.2	1.3	100	5.0	e
9	Spotchem SP-4430	141	98.6	0.7	0.7	111	6.9	e
10	Piccolo	69	97.2	1.4	1.4	105	4.8	e
11	Skyla	5	100.0	0.0	0.0	106	3.2	e
12	Reflotron	4	100.0	0.0	0.0	119	4.5	e*

One result was submitted but not published because the method group was too small. (< 4 results per group)


Triglycerides



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	15	100.0	0.0	0.0	1.76	3.8	e
2	Beckman	5	100.0	0.0	0.0	1.90	2.6	e
3	Roche	30	100.0	0.0	0.0	1.91	2.2	e
4	Siemens	5	100.0	0.0	0.0	1.90	5.3	e*
5	Autolyser	20	95.0	0.0	5.0	1.85	4.6	e
6	Selectra Pro	14	100.0	0.0	0.0	1.89	3.7	e
7	Fuji Dri-Chem	966	99.3	0.6	0.1	1.86	5.2	e
8	Spotchem D-Concept	451	97.8	0.0	2.2	1.79	5.3	e
9	Spotchem SP-4430	75	97.3	0.0	2.7	1.68	4.2	e
10	Piccolo	22	100.0	0.0	0.0	2.19	4.1	e
11	Cholestech LDX	273	99.2	0.4	0.4	1.75	4.6	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Lithium




QUALAB tolerance : 15 %

Lithium (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	6	100.0	0.0	0.0	1.54	2.8	e
2	Roche	14	100.0	0.0	0.0	1.59	4.3	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Lactate




QUALAB tolerance : 18 %

Lactate (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	7	100.0	0.0	0.0	4.89	3.2	e
2	Roche	16	100.0	0.0	0.0	4.86	3.6	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

HbA1c sample A




QUALAB tolerance : 9 %

HbA1c sample A (%)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	6	100.0	0.0	0.0	8.2	1.0	e
2	Roche, Cobas	19	100.0	0.0	0.0	8.4	2.3	e
3	HPLC	11	100.0	0.0	0.0	8.4	1.1	e
4	Afinion	511	97.6	1.2	1.2	8.3	2.4	e
5	Cobas b101	204	96.5	1.0	2.5	7.8	3.1	e
6	DCA2000/Vantage	136	97.1	0.7	2.2	8.1	3.4	e
7	Celltac chemi	21	100.0	0.0	0.0	7.9	4.0	e
8	NycoCard	8	75.0	12.5	12.5	8.4	5.1	c
9	Eurolyser	6	100.0	0.0	0.0	8.4	5.8	c
10	A1c Now	225	75.1	17.3	7.6	7.4	6.2	e
11	AFIAS	126	77.0	13.5	9.5	7.6	5.9	e
12	Others	20	100.0	0.0	0.0	8.2	2.5	e
13	Spinit	4	75.0	0.0	25.0	8.4	3.0	c

3 additional results were submitted but not published because the method groups were too small. (< results per group)

HbA1c sample B




QUALAB tolerance : 9 %

HbA1c sample B (%)

No.	Method	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	5	100.0	0.0	0.0	6.3	1.3	e
2	Roche, Cobas	18	100.0	0.0	0.0	6.4	3.3	e
3	HPLC	11	100.0	0.0	0.0	6.2	2.5	e
4	Afinion	751	99.4	0.3	0.3	6.1	2.3	e
5	Cobas b101	207	99.0	0.0	1.0	6.0	2.8	e
6	DCA2000/Vantage	186	98.4	1.1	0.5	6.3	3.2	e
7	Celltac chemi	20	100.0	0.0	0.0	5.9	4.3	e
8	NycoCard	5	80.0	20.0	0.0	6.3	4.7	c
9	Eurolyser	5	80.0	20.0	0.0	6.3	3.4	c
10	A1c Now	9	88.9	0.0	11.1	6.0	3.7	e*
11	AFIAS	182	85.2	10.4	4.4	5.9	5.7	e
12	Others	13	100.0	0.0	0.0	6.3	1.7	e
13	Quick Read go	5	100.0	0.0	0.0	6.6	1.7	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)


pCO₂

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	105	100.0	0.0	0.0	5.38	2.0	e
2	ABL90 FLEX / PLUS	117	98.3	0.0	1.7	5.57	1.9	e
3	Cobas b 123	16	100.0	0.0	0.0	5.64	1.0	e
4	Cobas b 221	5	100.0	0.0	0.0	5.76	3.1	e
5	GEM	9	100.0	0.0	0.0	5.73	1.4	e
6	iStat	51	96.1	0.0	3.9	4.82	3.5	e
7	EPOC	54	96.3	3.7	0.0	5.26	3.9	e
8	IL	4	100.0	0.0	0.0	5.60	1.5	e
9	Other methods	4	100.0	0.0	0.0	6.10	4.4	e*

8 additional results were submitted but not published because the method groups were too small. (< results per group)

K04 Blood gases

pO2



QUALAB tolerance : 15 %


pO2 (kPa)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	104	98.0	1.0	1.0	14.75	3.8	e
2	ABL90 FLEX / PLUS	118	97.5	0.0	2.5	13.55	3.2	e
3	Cobas b 123	18	100.0	0.0	0.0	14.25	3.8	e
4	GEM	9	100.0	0.0	0.0	14.40	3.2	e
5	iStat	48	87.5	4.2	8.3	15.76	6.2	e
6	EPOC	54	94.4	1.9	3.7	14.54	6.8	e
7	IL	4	100.0	0.0	0.0	14.25	1.5	e

13 additional results were submitted but not published because the method groups were too small. (< results per group)

K04 Blood gases


pH



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	103	100.0	0.0	0.0	7.39	0.1	e
2	ABL90 FLEX / PLUS	118	100.0	0.0	0.0	7.40	0.1	e
3	Cobas b 123	17	100.0	0.0	0.0	7.41	0.1	e
4	Cobas b 221	5	100.0	0.0	0.0	7.40	0.1	e
5	GEM	9	100.0	0.0	0.0	7.41	0.2	e
6	iStat	52	100.0	0.0	0.0	7.43	0.1	e
7	EPOC	54	100.0	0.0	0.0	7.39	0.1	e
8	IL	5	100.0	0.0	0.0	7.41	0.1	e

11 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose BG




QUALAB tolerance : 9 %

Glucose BG (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	GEM	5	100.0	0.0	0.0	5.7	1.0	e
2	Cobas b 123	11	100.0	0.0	0.0	5.5	2.1	e
3	iStat	11	100.0	0.0	0.0	5.4	1.7	e
4	EPOC	43	90.7	7.0	2.3	5.7	4.5	e
5	ABL700/800	95	100.0	0.0	0.0	5.7	2.2	e
6	ABL90 FLEX / PLUS	103	100.0	0.0	0.0	5.6	1.9	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)


Hemoglobin BG



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	97	94.8	0.0	5.2	126.7	1.7	e
2	ABL90 FLEX / PLUS	105	100.0	0.0	0.0	126.9	0.5	e
3	ABL80 FLEX CO-OX / O	5	100.0	0.0	0.0	125.0	3.0	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)


Potassium BG



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	GEM	6	100.0	0.0	0.0	3.8	1.5	e
2	Cobas b 123	19	94.7	0.0	5.3	3.8	0.7	e
3	iStat	20	100.0	0.0	0.0	3.8	1.1	e
4	EPOC	45	97.8	2.2	0.0	3.7	2.1	e
5	ABL700/800	96	99.0	1.0	0.0	3.8	1.4	e
6	ABL90 FLEX / PLUS	110	99.1	0.0	0.9	3.8	1.3	e

9 additional results were submitted but not published because the method groups were too small. (< results per group)


Sodium BG



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	GEM	7	100.0	0.0	0.0	139.0	0.4	e
2	Cobas b 123	19	94.7	0.0	5.3	138.3	0.5	e
3	iStat	20	90.0	5.0	5.0	141.8	2.1	e
4	EPOC	44	97.7	2.3	0.0	140.5	1.6	e
5	ABL700/800	95	98.9	0.0	1.1	140.6	0.8	e
6	ABL90 FLEX / PLUS	109	99.1	0.0	0.9	141.8	0.3	e

8 additional results were submitted but not published because the method groups were too small. (< results per group)

Chlorid-BG




QUALAB tolerance : 6 %

Chlorid-BG (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b 123	11	100.0	0.0	0.0	100.5	0.7	e
2	EPOC	18	94.4	0.0	5.6	100.1	1.6	e
3	ABL700/800	92	100.0	0.0	0.0	99.1	1.5	e
4	ABL90 FLEX / PLUS	104	100.0	0.0	0.0	97.2	0.4	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Calcium-BG




MQ tolerance : 12 %
(< 2.00: +/- 0.24 mmol/l)

Calcium-BG (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	GEM	6	100.0	0.0	0.0	0.44	1.4	e
2	Cobas b123	10	100.0	0.0	0.0	0.35	12.1	e*
3	Roche, Cobas	5	80.0	0.0	20.0	0.46	18.8	e*
4	iStat	15	93.3	0.0	6.7	0.48	1.6	e
5	EPOC	41	97.6	0.0	2.4	0.53	5.6	e
6	ABL700/800	95	100.0	0.0	0.0	0.53	4.1	e
7	ABL90 FLEX / PLUS	107	100.0	0.0	0.0	0.52	0.7	e


7 additional results were submitted but not published because the method groups were too small. (< results per group)

FHHb




No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL90 FLEX / PLUS	10	100.0	0.0	0.0	2.930	4.8	e
2 additional results were submitted but not published because the method groups were too small. (< results per group)								

Lactate-BG



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	GEM	6	100.0	0.0	0.0	1.80	4.1	e
2	Cobas b123	8	100.0	0.0	0.0	1.90	3.7	e
3	Roche, Cobas	4	75.0	25.0	0.0	1.85	10.9	e*
4	IL	4	100.0	0.0	0.0	1.70	7.3	e*
5	EPOC	42	97.6	0.0	2.4	1.74	2.2	e
6	iStat	17	100.0	0.0	0.0	1.60	2.2	e
7	ABL700/800	100	100.0	0.0	0.0	1.70	4.3	e
8	ABL90 FLEX / PLUS	112	99.1	0.9	0.0	1.59	3.3	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

sO2 OR


MQ tolerance : 20 %

sO2 OR (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat	24	100.0	0.0	0.0	98.833	0.4	e
2	ABL700/800	85	100.0	0.0	0.0	96.911	0.2	e
3	ABL90 FLEX / PLUS	95	100.0	0.0	0.0	96.939	0.1	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

FO2Hb OR




MQ tolerance : 20 %

FO2Hb OR (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	85	98.8	0.0	1.2	92.266	0.4	e
2	ABL90 FLEX / PLUS	96	100.0	0.0	0.0	92.152	0.1	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

FCOHb OR




MQ tolerance : 20 %

FCOHb OR (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	86	94.2	3.5	2.3	2.858	10.4	e
2	ABL90 FLEX / PLUS	96	100.0	0.0	0.0	2.939	5.5	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

FMetHb OR




MQ tolerance : 20 %

FMetHb OR (%)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	86	100.0	0.0	0.0	1.983	4.8	e
2	ABL90 FLEX / PLUS	96	99.0	0.0	1.0	2.003	3.5	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

FHbF OR




MQ tolerance : 20 %

FHbF OR (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL90 FLEX / PLUS	36	97.2	2.8	0.0	78.694	4.6	e
2 additional results were submitted but not published because the method groups were too small. (< results per group)								

Bilirubin OR




QUALAB tolerance : 18 %

Bilirubin OR (μmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	5	100.0	0.0	0.0	291.0	3.0	e
2	ABL90 FLEX / PLUS	35	100.0	0.0	0.0	292.3	0.7	e


Troponin I



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Pathfast	26	96.2	0.0	3.8	7116.6	8.6	e
2	Vidas	12	100.0	0.0	0.0	5510.6	10.2	e*
3	Abbott	11	100.0	0.0	0.0	2072.8	8.9	e

8 additional results were submitted but not published because the method groups were too small. (< results per group)


Troponin T



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas hs	12	91.7	0.0	8.3	2171.18	2.4	e
2	Cobas hs STAT	15	100.0	0.0	0.0	2153.07	2.6	e

One result was submitted but not published because the method group was too small. (< 4 results per group)

Myoglobin




QUALAB tolerance : 30 %

Myoglobin (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	7	100.0	0.0	0.0	118.0	2.3	e
2	Abbott	5	100.0	0.0	0.0	122.2	5.7	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

CK-MB mass




MQ tolerance : 40 %

CK-MB mass (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	4	100.0	0.0	0.0	18.0	2.3	e
2	Cobas E / Elecsys	10	100.0	0.0	0.0	20.5	3.2	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

BNP




QUALAB tolerance : 27 %

BNP (ng/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	5	100.0	0.0	0.0	724.1	2.2	a
2 additional results were submitted but not published because the method groups were too small. (< results per group)								


NT-proBNP



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Pathfast	20	90.0	5.0	5.0	2470.0	13.4	e
2	AQT 90 FLEX	5	100.0	0.0	0.0	2140.0	7.3	e*
3	VIDAS	9	100.0	0.0	0.0	1024.0	9.6	e
4	Cobas E / Elecsys	24	100.0	0.0	0.0	1269.5	6.1	e
5	Abbott	9	100.0	0.0	0.0	1384.6	5.1	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)


TSH



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	30	100.0	0.0	0.0	12.83	2.5	e
2	Abbott	13	100.0	0.0	0.0	9.98	3.3	e
3	VIDAS	14	100.0	0.0	0.0	14.22	7.1	e
4	Dimension	5	100.0	0.0	0.0	11.70	6.9	e*
5	AFIAS	8	50.0	37.5	12.5	15.71	16.9	e*
6	Other methods	4	100.0	0.0	0.0	11.72	7.2	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

T3




MQ tolerance : 20 %

T3 (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	4	100.0	0.0	0.0	3.1	2.7	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)


T4



MQ tolerance : 20 %

T4 (nmol/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	4	100.0	0.0	0.0	170	3.4	e
2 additional results were submitted but not published because the method groups were too small. (< results per group)								

FT3


QUALAB tolerance : 18 %

FT3 (pmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	26	100.0	0.0	0.0	13.3	4.1	e
2	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	12.9	9.0	e*
3	Abbott	11	100.0	0.0	0.0	11.1	4.1	e
4	VIDAS	7	100.0	0.0	0.0	12.3	5.2	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

FT4




QUALAB tolerance : 20 %

No. Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	27	100.0	0.0	0.0	45.3	3.3	e
2	Abbott	12	91.7	0.0	8.3	32.2	8.4	e*
3	VIDAS	8	100.0	0.0	0.0	45.1	3.6	e
4	Other methods	7	100.0	0.0	0.0	42.9	6.9	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Testosterone




QUALAB tolerance : 30 %

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	12	100.0	0.0	0.0	17.6	4.1	e
2	Siemens	6	100.0	0.0	0.0	16.5	3.9	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Estradiol




QUALAB tolerance : 30 %

Estradiol (pmol/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	10	100.0	0.0	0.0	1367	3.0	e
2	Siemens	5	100.0	0.0	0.0	2063	7.6	e
3	Abbott	6	100.0	0.0	0.0	1225	4.2	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

SHBG




MQ tolerance : 30 %

SHBG (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	16	100.0	0.0	0.0	38.1	3.9	e
2	Abbott	5	100.0	0.0	0.0	42.5	5.4	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Cortisol




QUALAB tolerance : 20 %

No. Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	22	100.0	0.0	0.0	664	3.0	e
2	Abbott	5	100.0	0.0	0.0	605	5.4	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Progesteron




MQ tolerance : 30 %

Progesteron (nmol/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	7	100.0	0.0	0.0	46.7	4.0	e
2	Abbott	5	100.0	0.0	0.0	36.0	7.0	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

DHEAS




MQ tolerance : 30 %

DHEAS ($\mu\text{mol/l}$)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	12	100.0	0.0	0.0	8.03	3.0	e
2	Abbott	4	100.0	0.0	0.0	6.62	10.1	e*

One result was submitted but not published because the method group was too small. (< 4 results per group)


Luteinizing hormone



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	11	100.0	0.0	0.0	34.8	3.0	e
2	Siemens	5	100.0	0.0	0.0	30.7	5.6	e
3	Abbott	6	100.0	0.0	0.0	24.9	5.5	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Follicle-stimulating hormone




QUALAB tolerance : 24 %

Follicle-stimulating hormone (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	11	100.0	0.0	0.0	22.7	5.6	e
2	Abbott	8	100.0	0.0	0.0	22.3	6.0	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Prolactine



QUALAB tolerance : 24 %

Prolactine (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas/Roche	12	100.0	0.0	0.0	31.3	2.3	e
2	Abbott	6	100.0	0.0	0.0	25.9	6.2	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Insulin




MQ tolerance : 25 %

Insulin (pmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	14	100.0	0.0	0.0	622	5.2	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)


HGH



MQ tolerance : 25 %


HGH (µg/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	7	100.0	0.0	0.0	13.50	3.2	e
2	Liaison	4	75.0	0.0	25.0	12.45	7.1	e*

IGF-1

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	7	100.0	0.0	0.0	104	16.9	a
2	Other methods	5	100.0	0.0	0.0	65	3.5	a

Troponin T CR




QUALAB tolerance : 24 %

Troponin T CR (ng/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas h 232	878	85.3	10.3	4.4	202.77	14.5	e

D-dimer CR




QUALAB tolerance : 21 %

D-dimer CR (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas h 232	976	89.6	7.0	3.4	0.43	12.0	e
2	Lumira Dx	6	100.0	0.0	0.0	0.46	7.4	e*

CKMB- K8




MQ tolerance : 40 %

CKMB- K8 (μg/l)


No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas h 232	6	100.0	0.0	0.0	16.5	9.0	e

NT-proBNP CR




No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Lumira Dx	4	100.0	0.0	0.0	428	8.0	e*
2	Cobas h 232	603	97.5	2.2	0.3	150	30.1	a

PCO2 CCA




No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	11	100.0	0.0	0.0	9.27	3.3	e

PO2 CCA




No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	11	100.0	0.0	0.0	9.60	7.9	e*

pH CCA



No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	10	100.0	0.0	0.0	7.14	0.2	e


Potassium CCA



QUALAB tolerance : 6 %
(< 3.3: +/- 0.2 mmol/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	5	100.0	0.0	0.0	2.9	2.0	e*


Sodium CCA



QUALAB tolerance : 6 %

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	4	100.0	0.0	0.0	125.9	1.1	e

Ferritin




QUALAB tolerance : 24 %

Ferritin (µg/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Dimension	5	100.0	0.0	0.0	81.30	5.0	e
2	Beckman	6	100.0	0.0	0.0	60.00	13.1	a
3	all Participants	6	100.0	0.0	0.0	53.80	20.8	a
4	Roche, Cobas	30	100.0	0.0	0.0	75.16	6.3	e
5	Abbott	13	100.0	0.0	0.0	95.50	4.8	e
6	Mini Vidas	7	85.7	14.3	0.0	58.70	12.5	e*
7	AFIAS	27	100.0	0.0	0.0	58.03	4.5	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Vitamin B12




QUALAB tolerance : 21 %

Vitamin B12 (pmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	5	100.0	0.0	0.0	225.50	6.7	e*
2	Roche, Cobas	21	100.0	0.0	0.0	263.97	5.1	e
3	Abbott	12	91.7	8.3	0.0	243.70	9.6	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Folate




QUALAB tolerance : 24 %

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens	6	83.3	0.0	16.7	49.10	14.6	a
2	Roche, Cobas	22	100.0	0.0	0.0	37.36	5.9	e
3	Abbott	11	100.0	0.0	0.0	35.33	6.7	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Holotranscobalamine




MQ tolerance : 30 %

Holotranscobalamine (pmol/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	15	93.3	6.7	0.0	73.0	10.7	e
2	Abbott	18	100.0	0.0	0.0	84.8	7.0	e
3	Cobas Biotin suppres	19	100.0	0.0	0.0	50.9	7.4	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Bilirubin total Neo




QUALAB tolerance : 18 %

Bilirubin total Neo (μmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	16	100.0	0.0	0.0	88	4.9	e
2	Dimension	5	100.0	0.0	0.0	101	4.4	e

Bilirubin direct




QUALAB tolerance : 18 %

Bilirubin direct (μmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	23	100.0	0.0	0.0	57	7.4	e
3 additional results were submitted but not published because the method groups were too small. (< results per group)								

Bilirubin neonatal




QUALAB tolerance : 18 %

Bilirubin neonatal (μmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	10	100.0	0.0	0.0	107	6.2	e
2	Other methods	12	100.0	0.0	0.0	120	3.5	e

PSA




QUALAB tolerance : 21 %

PSA (µg/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	18	100.0	0.0	0.0	7.76	3.6	e
2	Abbott	8	87.5	0.0	12.5	7.33	4.6	e
3	AFIAS	12	100.0	0.0	0.0	8.09	6.6	e

8 additional results were submitted but not published because the method groups were too small. (< results per group)

free PSA




QUALAB tolerance : 21 %

free PSA (µg/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	11	100.0	0.0	0.0	1.64	3.2	e
2	Abbott	7	100.0	0.0	0.0	1.71	6.9	e*

6 additional results were submitted but not published because the method groups were too small. (< results per group)

CEA




QUALAB tolerance : 21 %

CEA (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	12	100.0	0.0	0.0	5.7	3.6	e
2	Abbott	7	100.0	0.0	0.0	7.7	7.1	e*

7 additional results were submitted but not published because the method groups were too small. (< results per group)

CA 125




MQ tolerance : 25 %

CA 125 (kIU/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	8	100.0	0.0	0.0	57.5	1.3	e
2	Abbott	7	100.0	0.0	0.0	93.0	7.0	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

CA 19-9




MQ tolerance : 25 %

CA 19-9 (kIU/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	7	100.0	0.0	0.0	30.0	4.6	e
2	Abbott	5	80.0	0.0	20.0	226.3	3.7	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

CA 15-3




MQ tolerance : 25 %

CA 15-3 (kIU/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	10	100.0	0.0	0.0	21.3	5.1	e
2	Siemens	4	100.0	0.0	0.0	19.1	11.4	e*
3	Abbott	7	100.0	0.0	0.0	24.2	3.0	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)


AFP



No. Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	7	100.0	0.0	0.0	9.6	11.5	e*
2	Abbott	5	100.0	0.0	0.0	8.2	5.0	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

HCG qn




QUALAB tolerance : 21 %

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	16	100.0	0.0	0.0	33.9	4.5	e
2	VIDAS	11	100.0	0.0	0.0	11.5	9.2	e*
3	Abbott	9	100.0	0.0	0.0	34.0	5.6	e
4	AFIAS	9	88.9	11.1	0.0	53.0	11.7	e*

9 additional results were submitted but not published because the method groups were too small. (< results per group)

HCG intact




QUALAB tolerance : 25 %

HCG intact (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	5	100.0	0.0	0.0	9.5	4.5	e

One result was submitted but not published because the method group was too small. (< 4 results per group)

S100




MQ tolerance : 25 %

S100 (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	6	100.0	0.0	0.0	0.58	2.0	e

One result was submitted but not published because the method group was too small. (< 4 results per group)

NSE




MQ tolerance : 25 %

NSE (ng/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	5	100.0	0.0	0.0	8.8	6.0	e
One result was submitted but not pubished because the method group was too small. (< 4 results per group)								


Thyreoglobulin



MQ tolerance : 25 %

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	4	100.0	0.0	0.0	55.2	0.6	e
2	Other methods	4	100.0	0.0	0.0	96.2	10.3	e*

CK-MB




MQ tolerance : 30 %

CK-MB (U/l)

No. Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Fuji Dri-Chem	20	100.0	0.0	0.0	69.6	8.0	e
2	Cobas/Roche	7	100.0	0.0	0.0	29.7	3.4	e


2 additional results were submitted but not published because the method groups were too small. (< results per group)

C-Peptid



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	7	100.0	0.0	0.0	1.44	6.1	e
2	Other methods	5	100.0	0.0	0.0	1.28	13.4	d

ACTH




MQ tolerance : 25 %

ACTH (ng/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	8	100.0	0.0	0.0	17.76	10.0	e*
3 additional results were submitted but not published because the method groups were too small. (< results per group)								


Procalcitonin



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	8	100.0	0.0	0.0	2.75	10.7	e*
2	Cobas	16	100.0	0.0	0.0	2.03	2.9	e
3	VIDAS	15	100.0	0.0	0.0	1.74	6.8	e
4	Liaison	4	75.0	25.0	0.0	4.36	17.6	e*

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Parathyroid hormone




QUALAB tolerance : 24 %

Parathyroid hormone (pmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas PTH STAT	9	100.0	0.0	0.0	26.8	4.0	e
2	Cobas	12	100.0	0.0	0.0	20.7	3.5	e
3	IDS	4	100.0	0.0	0.0	38.4	12.2	e*
4	Abbott	7	100.0	0.0	0.0	46.1	16.5	a


6 additional results were submitted but not published because the method groups were too small. (< results per group)

Osmolality



No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cryoskopy	22	100.0	0.0	0.0	404	1.2	e

Potassium-K22




QUALAB tolerance : 6 %

Potassium-K22 (mmol/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ISE	11	100.0	0.0	0.0	3.7	2.5	a

Sodium-K22




QUALAB tolerance : 6 %

Sodium-K22 (mmol/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ISE	11	100.0	0.0	0.0	144	1.1	e


Glucose-K22



QUALAB tolerance : 9 %

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	11	100.0	0.0	0.0	4.4	2.5	e

Urea-K22




QUALAB tolerance : 15 %

Urea-K22 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	11	100.0	0.0	0.0	4.2	5.6	e

Osmotic Gap




MQ tolerance : 40 %

Osmotic Gap (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Formel 1 (2Na+K+Glu+	9	100.0	0.0	0.0	107.6	5.3	e
2 additional results were submitted but not published because the method groups were too small. (< results per group)								

Digoxin




QUALAB tolerance : 24 %

Digoxin (nmol/l)


No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Alinity	4	100.0	0.0	0.0	2.69	6.1	e*
2	Other methods	8	100.0	0.0	0.0	2.93	7.6	a

Phenytoin




No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	67	4.2	a

Phenobarbital



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	174	4.0	e

Paracetamol




MQ tolerance : 25 %

Paracetamol (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	5	100.0	0.0	0.0	401.0	4.4	e
One result was submitted but not pubished because the method group was too small. (< 4 results per group)								

Vancomycin




MQ tolerance : 25 %

Vancomycin (μmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	5	100.0	0.0	0.0	16.8	4.2	a
2	Abbott	4	100.0	0.0	0.0	20.2	8.5	d


2 additional results were submitted but not published because the method groups were too small. (< results per group)

Valproat




No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	9	100.0	0.0	0.0	683.6	6.6	a

Carbamazepin



No. Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 all Participants	5	100.0	0.0	0.0	45.8	8.2	e*


Cystatin C



MQ tolerance : 24 % Cystatin C (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	19	94.7	0.0	5.3	2.58	4.2	e
2 additional results were submitted but not published because the method groups were too small. (< results per group)								

Ethanol




QUALAB tolerance : 18 %

Ethanol (mmol/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Others	5	60.0	0.0	40.0	47.7	2.7	e
2	Abbott	9	100.0	0.0	0.0	44.9	2.5	e
3	Roche, Cobas	21	100.0	0.0	0.0	43.9	2.8	e

Ammonia




QUALAB tolerance : 21 %

Ammonia (μmol/l)

No. Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	5	100.0	0.0	0.0	210.6	9.2	e*
2	all Participants	8	100.0	0.0	0.0	259.5	3.7	e

Calprotectin




MQ tolerance : 40 %
(< 50: +/- 20 µg/g)

Calprotectin (µg/g)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Bühlmann fCALturbo	21	90.5	0.0	9.5	286	13.1	e
2	Bühlmann Quantum Blu	5	80.0	20.0	0.0	123	29.1	e*
3	Liaison	14	92.9	0.0	7.1	41	22.1	e*


4 additional results were submitted but not published because the method groups were too small. (< results per group)

Cholesterol total Af/b101


QUALAB tolerance : 10 %

Cholesterol total Af/b101 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b101	312	100.0	0.0	0.0	5.86	2.3	e
2	Afinion	442	98.7	1.1	0.2	5.66	3.6	e

Cholesterol HDL Af/b101

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b101	309	95.2	0.3	4.5	1.30	4.1	e
2	Afinion	440	94.8	0.2	5.0	1.16	4.4	e


Tryglycerides Af/b101

QUALAB tolerance : 18 %

Tryglycerides Af/b101 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b101	309	99.1	0.3	0.6	2.01	2.5	e
2	Afinion	443	99.6	0.2	0.2	1.97	4.5	e

Cholesterol PTS




QUALAB tolerance : 10 %

Cholesterol PTS (mmol/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CardioChek	5	40.0	40.0	20.0	5.02	9.1	e*

Cholesterol HDL PTS




QUALAB tolerance : 21 %

Cholesterol HDL PTS (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CardioChek	5	0.0	0.0	100.0	1.30	0.0	a

Triglycerides



QUALAB tolerance : 18 %

Triglycerides (mmol/l)


No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CardioChek	5	100.0	0.0	0.0	1.82	4.7	e

Troponin I AFIAS



No.Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 AFIAS	429	87.4	6.3	6.3	197.00	12.6	e

NT-proBNP AFIAS




QUALAB tolerance : 27 %

NT-proBNP AFIAS (ng/l)

No.Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 AFIAS	321	93.7	4.7	1.6	372.2	11.8	e


Homocystein



MQ tolerance : 30 %

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Beckman	6	100.0	0.0	0.0	31.4	2.6	e
2	all Participants	6	100.0	0.0	0.0	26.8	10.0	e*


Lipase



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	15	100.0	0.0	0.0	77.9	8.2	e
2	Beckman	5	100.0	0.0	0.0	79.7	1.8	e
3	Roche	28	100.0	0.0	0.0	82.2	5.5	e
4	Fuji Dri-Chem	172	99.4	0.0	0.6	71.7	5.2	e

12 additional results were submitted but not published because the method groups were too small. (< results per group)

Fructosamine




MQ tolerance : 15 %

Fructosamine (μmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	4	100.0	0.0	0.0	515	1.9	e

One result was submitted but not published because the method group was too small. (< 4 results per group)

Bicarbonat




MQ tolerance : 15 %

Bicarbonat (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	6	100.0	0.0	0.0	20.4	7.8	e*
2	Piccolo	4	100.0	0.0	0.0	24.5	3.9	e*
3	Abbott	4	100.0	0.0	0.0	20.8	2.4	e

One result was submitted but not published because the method group was too small. (< 4 results per group)


Cholinesterase



MQ tolerance : 30 % Cholinesterase (kU/L)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens	4	100.0	0.0	0.0	8.6	13.3	e*
3 additional results were submitted but not published because the method groups were too small. (< results per group)								

Glucose CSF




QUALAB tolerance : 9 %

Glucose CSF (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	14	100.0	0.0	0.0	3.44	1.9	e
2	Other methods	15	100.0	0.0	0.0	3.38	2.6	e

Lactate CSF




QUALAB tolerance : 18 %

Lactate CSF (mmol/l)


No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	12	100.0	0.0	0.0	1.90	2.8	e
2	Other methods	13	92.3	7.7	0.0	1.90	9.8	e*

Protein CSF



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	19	100.0	0.0	0.0	0.37	3.6	e
2	Other methods	7	100.0	0.0	0.0	0.41	6.4	e*

One result was submitted but not published because the method group was too small. (< 4 results per group)


Albumine CSF

MQ tolerance : 20 %

Albumine CSF (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	5	100.0	0.0	0.0	224.20	3.1	a
2	Other methods	4	100.0	0.0	0.0	241.50	2.9	e

CDT




MQ tolerance : 20 %

CDT (%)


No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Immunoassay	6	100.0	0.0	0.0	1.30	4.1	e
3 additional results were submitted but not published because the method groups were too small. (< results per group)								

Tacrolimus



No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	9	100.0	0.0	0.0	16.5	7.5	a

Totalprotein E




MQ tolerance : 12 %

Totalprotein E (g/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	19	100.0	0.0	0.0	69.9	3.2	e

Albumin E




MQ tolerance : 12 %

Albumin E (%)


No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	32	96.9	0.0	3.1	64.3	4.1	e

alpha-1-Globuline



No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	12	100.0	0.0	0.0	2.7	8.3	e
2	capillary electropho	20	100.0	0.0	0.0	4.4	10.8	e


alpha-2-Globuline



MQ tolerance : 30 %


No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	32	100.0	0.0	0.0	11.6	8.3	e

beta-Globuline



No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	15	100.0	0.0	0.0	9.4	8.6	e

Beta-1-Globulin




MQ tolerance : 30 %

Beta-1-Globulin (%)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	12	100.0	0.0	0.0	7.3	3.3	e

Beta-2-Globulin




MQ tolerance : 30 %

Beta-2-Globulin (%)


No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	11	100.0	0.0	0.0	3.2	8.5	e

gamma-Globuline



No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	13	100.0	0.0	0.0	9.9	15.7	e*


Gamma-Globuline+P



MQ tolerance : 30 %

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	19	100.0	0.0	0.0	10.2	8.7	e

Paraprotein




MQ tolerance : 30 %

Paraprotein (%)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	4	100.0	0.0	0.0	0.0	0.0	e

Beta-Globuline+P




MQ tolerance : 30 %

Beta-Globuline+P (%)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	5	100.0	0.0	0.0	10.4	10.3	e*

Immunfixation




QUALAB tolerance : 1 %

Immunfixation (Code)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Interpretation	27	81.5	0.0	18.5	5	0.0	a

Folate in Erythrocytes




MQ tolerance : 40 %

Folate in Erythrocytes (nmol/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens	4	100.0	0.0	0.0	599	14.9	a
2	Abbott	10	90.0	0.0	10.0	214	11.8	e
3	Roche, Cobas	22	100.0	0.0	0.0	1268	8.4	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Gallensäure




MQ tolerance : 30 %

Gallensäure (μmol/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	9	100.0	0.0	0.0	37.5	7.0	e
2	all Participants	17	100.0	0.0	0.0	30.9	9.4	e

BNP




QUALAB tolerance : 27 %
(< 75.0: +/- 20.0 ng/l)

BNP (ng/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Triage	8	100.0	0.0	0.0	14.9	53.7	e*

Troponin I Triage




QUALAB tolerance : 24 %

Troponin I Triage (ng/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Triage high sensitiv	233	87.6	9.0	3.4	434.43	14.0	e
2	Triage Next Gen	6	66.7	0.0	33.3	10.00	0.0	e


2 additional results were submitted but not published because the method groups were too small. (< results per group)

NT-pro BNP



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Triage	121	91.7	6.6	1.7	343	13.6	e

Vitamin D 25 (OH)




QUALAB tolerance : 27 %

Vitamin D 25 (OH) (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	20	100.0	0.0	0.0	100.0	6.3	e
2	VIDAS	6	100.0	0.0	0.0	90.1	4.2	e
3	Other methods	8	62.5	12.5	25.0	107.2	19.8	e*
4	Abbott	11	90.9	9.1	0.0	108.9	10.8	e*
5	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	82.4	7.7	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

AMH




No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	19	94.7	0.0	5.3	16.7	4.8	e
3 additional results were submitted but not published because the method groups were too small. (< results per group)								

Inhibin B



No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	7	85.7	14.3	0.0	168.7	12.2	a

Calcitonin




MQ tolerance : 25 %

Calcitonin (pmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	5	100.0	0.0	0.0	5.7	6.9	e*
2	Other methods	7	85.7	0.0	14.3	20.6	4.4	a

IGF-BP3




MQ tolerance : 25 %

IGF-BP3 (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	7	100.0	0.0	0.0	3.20	4.6	d

One result was submitted but not published because the method group was too small. (< 4 results per group)

Renin




MQ tolerance : 25 %

Renin (mU/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	9	100.0	0.0	0.0	69.0	5.5	d

One result was submitted but not published because the method group was too small. (< 4 results per group)


Aldosteron



MQ tolerance : 30 % Aldosteron (ng/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	5	100.0	0.0	0.0	49.2	16.8	a
2 additional results were submitted but not published because the method groups were too small. (< results per group)								

Anti Thyreoglobulin




MQ tolerance : 25 %

Anti Thyreoglobulin (IU/ml)

No. Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Alinity	6	100.0	0.0	0.0	15	12.8	a
2	Roche, Cobas	11	100.0	0.0	0.0	63	6.2	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti TPO




QUALAB tolerance : 25 %

No. Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	13	100.0	0.0	0.0	117	6.2	e
2	Abbott	7	100.0	0.0	0.0	171	10.6	e*


5 additional results were submitted but not published because the method groups were too small. (< results per group)

TRAK




No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	6	100.0	0.0	0.0	6.69	4.6	e
2	Roche, Cobas	8	100.0	0.0	0.0	4.83	5.1	e
3	Kryptor	4	100.0	0.0	0.0	4.19	4.1	e

Creatinine WB



No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Statsensor i / Nova	79	87.3	3.8	8.9	300	9.4	e

eGFR CDK-EPI WB




MQ tolerance : 30 %

eGFR CDK-EPI WB ()

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Statsensor i / Nova	4	100.0	0.0	0.0	16	8.7	e*

IL6




MQ tolerance : 30 %

IL6 (ng/l)


No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	6	100.0	0.0	0.0	40.6	4.7	e

Pankreas Elastase




No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	14	100.0	0.0	0.0	355	19.9	e*

Copeptin



No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Kryptor	7	100.0	0.0	0.0	19.1	10.9	e*

Occult blood qn




MQ tolerance : 30 %

Occult blood qn (ng/ml)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OC-Sensor	4	100.0	0.0	0.0	1	0.0	e

Amylase-Urine




MQ tolerance : 25 %

Amylase-Urine (U/l)

No.Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 IFCC	6	100.0	0.0	0.0	143	5.8	e

Pancreatic Amylase-Urine




QUALAB tolerance : 18 %
(< 25.0: +/- 5.0 U/l)

Pancreatic Amylase-Urine (U/l)

No.Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 IFCC	4	100.0	0.0	0.0	5.0	15.9	e*

Calcium-Urine




MQ tolerance : 9 %

Calcium-Urine (mmol/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	17	100.0	0.0	0.0	2.24	2.5	e
2	Abbott	12	100.0	0.0	0.0	2.15	1.7	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Chloride-Urine



MQ tolerance : 12 %

Chloride-Urine (mmol/l)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	12	100.0	0.0	0.0	156	0.9	e
2	Roche, Cobas	13	100.0	0.0	0.0	149	1.9	e


2 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose-Urine



No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	27	96.3	0.0	3.7	12.1	2.1	e


Magnesium-Urine



MQ tolerance : 12 % Magnesium-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	18	100.0	0.0	0.0	2.89	4.2	e
2 additional results were submitted but not published because the method groups were too small. (< results per group)								

Osmolality-Urine




MQ tolerance : 10 %

Osmolality-Urine (mosm/kg)

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cryoskopy	21	100.0	0.0	0.0	707	0.8	e

Phosphate-Urine




No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	28	100.0	0.0	0.0	14.3	3.2	e

Potassium-Urine



No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	38	97.4	2.6	0.0	61	4.5	e

Protein-Urine




QUALAB tolerance : 15 %

Protein-Urine (mg/l)

No. Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	23	100.0	0.0	0.0	406.6	2.6	e
2	Abbott	17	100.0	0.0	0.0	499.6	2.8	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Sodium-Urine




MQ tolerance : 15 %

Sodium-Urine (mmol/l)


No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	38	100.0	0.0	0.0	141	2.0	e

Urea-Urine



No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	36	100.0	0.0	0.0	235	4.3	e

Uric Acid-Urine




MQ tolerance : 15 %

Uric Acid-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	26	100.0	0.0	0.0	0.91	3.9	e
2 additional results were submitted but not published because the method groups were too small. (< results per group)								

Specific Gravity-Urine




MQ tolerance : 5 %

Specific Gravity-Urine ()


No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Refractometer	5	100.0	0.0	0.0	1.020	0.2	e

Ethylglucuronid



No.Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1 all Participants	4	100.0	0.0	0.0	0.83	7.8	a


Creatinine U



No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	14	100.0	0.0	0.0	72.5	3.6	e
2	Roche, Cobas	20	95.0	5.0	0.0	65.5	7.6	e
3	Aution	8	62.5	0.0	37.5	80.0	4.0	a
4	AFIAS	16	93.7	6.3	0.0	75.1	12.2	e*
5	Afinion	507	96.8	1.2	2.0	70.9	8.4	e
6	Sysmex U	16	75.0	0.0	25.0	80.0	0.0	e
7	Other methods	4	75.0	0.0	25.0	80.0	0.0	e
8	DCA2000/Vantage	152	88.8	2.0	9.2	74.2	8.0	e
9	Siemens Clinitek	24	95.8	0.0	4.2	80.0	0.0	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)


Creatinin Urin



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	14	100.0	0.0	0.0	5.9	4.0	e
2	Roche	27	100.0	0.0	0.0	6.2	3.9	e
3	Beckman	4	100.0	0.0	0.0	6.6	6.0	e*
4	Siemens	5	100.0	0.0	0.0	6.0	3.0	e
5	DCA2000/Vantage	149	86.6	1.3	12.1	6.4	6.4	e
6	Afinion	502	97.8	0.2	2.0	5.7	4.7	e
7	Sysmex U	12	66.7	0.0	33.3	4.4	0.0	e
8	Aution	8	50.0	12.5	37.5	4.4	10.4	a
9	Siemens Clinitek	22	40.9	0.0	59.1	4.4	0.2	a
10	Other methods	5	80.0	0.0	20.0	4.4	0.0	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

HBV NAT qn




HBV NAT qn (Log10 IU/m)

QUALAB tolerance : +/- 0.50 Log10 IU/m

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	100.0	0.0	0.0	2.72	2.3	e*

HCV NAT qn




HCV NAT qn (Log10 IU/m)

QUALAB tolerance : +/- 0.50 Log10 IU/m

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	9	100.0	0.0	0.0	4.84	4.2	a

HIV1 NAT qn



HIV1 NAT qn (Log10 cp/m)

QUALAB tolerance : +/- 0.50 Log10 cp/m

No.Methode		Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	7	100.0	0.0	0.0	0.00	0.0	e